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Abstract: Treatment strategies for tumour diseases are progressively focusing on 
personalization of medicine. However, this focus requires methods revealing the early 
general biological mechanisms, including the formation anti-cancer drugs’ resistance. The 
low molecular mass protein metallothionein is thought to be the crucial for the formation of 
resistance in tumour treatment based on the platinum-cytostatics. The interactions between 
metallothionein (MT) and cisplatin were determined by the adsorptive transfer stripping 
technique coupled with the differential pulse votlammetry Brdicka´s reaction. The signals 
related to the MT-cisplatin complex appeared at -0.9 V. The formation of this complex 
depended on the time of interaction between cisplatin and MT. The complex formation was 
consequently confirmed by quartz crystal microbalance analyses. The formation of this 
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complex was detectable even after a 20 s long interaction. Moreover, we detected presence 
of MT-cisplatin complex in the blood of male rats treated with this drug. 
 
Keywords: Cancer; Metallothionein; Cisplatin; Protein-Drug Interaction; Voltammetry; 
Brdicka´s reaction; Quartz Crystal Microbalance;  
 
 
1. Introduction 
 
The metallothioneins (MT) are the group of the low molecular mass (about 6.5 kDa) heavy metal 
binding proteins. MTs are a family of proteins with a large degree of sequence homology, which are 
found in bacteria, fungi, plants, and animal species. They consist of approximately 65 amino acids 
with an extremely high occurrence of cysteine residues. The metal binding domain of MT consists of 
20 cysteine residues juxtaposed with the basic amino acids (lysine and arginine) arranged in two thiol-
rich sites [1-3]. Thiol-rich sites bind heavy metals ions with different affinity [4]. Due to their main 
ability of binding heavy metals MT play a crucial role in the maintenance of homeostasis of the 
essential metals ions. It was found that MT synthesis increased with the increase of essential as well as 
toxic heavy metals ions. Thus, MT levels are considered a biochemical marker of acute poisoning by 
heavy metals ions [5-8]. Besides this metallothionein gene can be inserted into plants to enhance their 
ability to withstand higher concentrations of heavy metal ions in the environment [9,10]. From a 
clinical point of view, MT appear to be markers of the enhanced cell proliferation and probably play a 
considerable role in the formation of the resistance to platinum-based-drug therapy [3,11]. 
For the determination of MT the various techniques and methods are employed, including the most 
commonly used immunochemistry [12-15]. Spectrometric [13,15,16] and chromatographic ones [17-
19] can also be used, although electrochemical methods are among the most sensitive, low cost and 
easy to use, with detection limits below nM [20]. In spite of the large battery of the techniques 
available detection of MT in the blood or blood serum is still a difficult task. Recently we have shown 
that serum MT levels of patients with a tumour disease were significantly enhanced [11,21,22]. In 
addition, the enhanced MT level was associated with the progression of the malignant disease. There 
are several other authors and research groups interested in the study of the relationship between MT 
with tumour disease progression. Recently, papers reporting the role of metallothionein in breast 
tumours [23,24], thyroidal tumours [25,26], prostate gland tumours [27-29], head and neck tumours 
[30] and liver tumours [31,32] were published. 
Platinum complexes play an important role in the chemotherapy of the various malignancies. In 
spite of the fact that the first platinum complex, cisplatin, was first used almost forty years ago, the 
exact mechanism of action remains unclear [33]. A platinum based cytostatic drug can coordinate to 
N7 of two neighbouring guanine and/or adenine bases, in the same or in opposite DNA strands, as this 
nitrogen does not form H bonds with the other bases [34]. The transport of cisplatin into a cell is the 
other crucial step. The cells treated with cisplatin protect themselves against it with the various 
mechanisms. Efflux of this drug by ATP pumps is one of them. Another very important mechanism of 
cisplatin resistance is based on the action of the enzyme glutathione-S-transferase (GST). GST 
transports cisplatin to reduced glutathione (GSH) and the GS-cisplatin complex is excreted out of cells. 
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In addition to the above mentioned mechanisms, MT can interact with cisplatin too [12,35,36]. MT 
binds molecules of cisplatin that are consequently excreted out of a cell (Figure 1). However the exact 
role of MT in formation of resistance on platinum based-cytostatics remains unclear. 
 
Figure 1. A simplified scheme of the possible reactions in a cell after cisplatin entry. 
Cisplatin can enter a cell through channels (e.g. CTRI) or also by the passive diffusion. In 
the cell, aqua complexes of cisplatin are able to react with DNA especially due to changes 
in chloride ion concentrations. However, cisplatin concentration in a cell is lowered by the 
active efflux through ATP pump and by reactions with glutathione and metallothionein. 
The scheme was proposed and modified according to [37,38]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As a consequence of the use of platinum based cytostatic drugs in the treatment of tumour diseases, 
it became necessary not only to detect them in the biological samples but also to investigate their 
interactions with intracellular peptides and proteins. The study of these interactions is still difficult 
task. Various spectrometric techniques such as the mass spectrometry, atomic absorption spectrometry 
or UV-VIS spectrometry, coupled with appropriate separation techniques, are used for this purpose 
and have been reviewed by Timerbaev et al. [39]. Computational approaches are used too [40-42] The 
adsorptive transfer stripping technique (AdTS) has many use advantages for studying heavy metal-
protein interactions [5,11,20,22,35-37,43-50]. A scheme of AdTS is shown in Figure 2. Besides AdTS, 
the quartz crystal microbalance represents another very promising tool in interaction studies [51-54]. 
The main aim of this work was to study the interaction of MT with cisplatin by using AdTS coupled 
with differential pulse voltammetry and a quartz crystal microbalance. 
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Figure 2. The principle of the adsorptive transfer stripping (AdTS) technique is based on 
the strong adsorption of the analyte on the electrode surface at the open electrode circuit. 
(a) A hanging mercury drop electrode surface is renewed. (b) The renewed electrode is 
immersed in a drop containing a target molecule (metallothionein) to be adsorbed on the 
surface of this electrode. (c and d) The excess analyte is rinsed from the surface of the 
working electrode in the buffer and the electrode is transferred to the solution containing a 
compound with which molecules adsorbed in previous step interacts. After the other 
rinsing step (e) the adsorbed complex is detected in the presence of supporting electrolyte 
(f) [35,36,46,50]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Results and Discussion 
 
2.1. Metallothionein-cisplatin interaction 
 
We have studied primarily the interaction of MT with cisplatin by Brdicka´s reaction. This method 
was used for decades for the determination of peptides and proteins rich in thiol moieties [36,49,55-
57]. Coupling of Brdicka´s reaction with AdTS seems to be a very promising tool for the detection of 
compounds rich in thiols [49]. The complexation of the cisplatin and MT and the subsequent reduction 
of the complexes at the electrode is one of possible modifications of Brdicka´s reaction to determine 
MT [58,59]. It could be suggested that cisplatin-MT complexes can be easily formed. Our experiments 
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were carried out accordingly. MT (5 µL, 10 µg mL-1) was placed on Parafilm. A hanging mercury drop 
electrode (HMDE) was subsequently immersed into this drop. MT was accumulated for 120 s onto the 
surface of immersed HMDE. After the accumulation step, HMDE was rinsed. MT has very good 
affinity to HMDE surface and forms an organised layer on the HMDE surface after a short time period 
[50]. The MT-modified HMDE was subsequently transferred into a microlitre volume of cisplatin. 
After a certain time interval, the electrode was rinsed and transferred into the supporting electrolyte, 
where the electrochemical detection was carried out. MT itself gave the typical Brdickas’ signals as 
RS2Co, Cat1, Cat2 and Cat3 [49,56]. The changes in Cat2 height with the increasing time of the 
interaction with cisplatin are shown in Figure 3. The Cat2 peak was decreasing with the increasing 
time of interaction. After 5 min long interaction, the decrease was higher than 95 %. 
 
Figure 3. The changes of catalytic Cat2 peak height during MT (10 µg mL-1) interaction 
with cisplatin (100 µg mL-1), n = 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. Electrochemical study of metallothionein-cisplatin complexes in rat blood   
 
The presence of MT-cisplatin complex was confirmed also on the rats treated intraperitoneally with 
cisplatin. After cisplatin application, blood was sampled from the tail. Samples were prepared by heat 
treatment and analysed by the AdTS differential pulse voltammetry Brdicka´s reaction. Figure 4 shows 
DP voltammograms of blood obtained from rats in certain time intervals. It is clearly shown that the 
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other hand Cat2 signal decreased. Cat2 is due to presence of free –SH moieties [49]. MT interacts with 
cisplatin via these moieties. Therefore, a decline of this signal correlates well with the fact that free 
thiol moieties of MT are saturated by cisplatin. This finding encouraged us to use other method to 
study the interaction of MT with cisplatin. 
 
Figure 4. DP voltammograms of the rats´ blood treated with cisplatin for certain time 
intervals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Detection of MT by quartz crystal microbalance 
 
In addition to mercury electrodes, MT is characterized by its high affinity for gold electrodes. Thus, 
we studied interaction of MT with a gold crystal by the changes in frequency of the crystal. The 
instrument used for this purpose is shown in Figure 5. A Teflon body containing a gold electrode was 
rinsed with supporting electrolyte with the use of a peristaltic pump. We observed changes in the 
frequency of the gold crystal with increasing MT concentration. The dependence obtained is shown in 
Figure 5A. Typical signals of the frequency change after introducing of 0, 0.5, 5, 20 and 50 µg mL-1 
MT are shown in Figure 5B. We found that the frequency decreased as the MT concentration 
increased, according to the following equation: y = -8.0405x + 38.359 (R2 = 0.9746; R.S.D. = 4.5%). 
For analytical purposes we attempted to divide the concentration interval into two parts. The first part 
(concentration of MT = 0.5 – 7.5 M) was strictly linear (y = -15.537x + 66.907; R2 = 0.9959). The 
second part (concentration of MT = 7.5 – 50 M) had the following parameters: y = -6.9575x + 0.416; 
R2 = 0.9999; R.S.D. = 6.1%. We used the first part of this curve to determine the average change in 
frequency per 1 ng of MT. One ng of MT caused an approx. 3 Hz decrease in the frequency. Further, 
we used QCM to study the MT interaction with cisplatin. The experiment was carried out similarly as 
in case of HMDE. A gold electrode was modified by MT and immersed into a solution of cisplatin. 
The measured frequency decreased with as the interaction time increased (Figure 6). The highest 
decrease was determined after 90 s long MT-cisplatin interaction. Then, the signal decreased 
gradually. 
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Figure 5. QCM analysis of MT on the gold crystal. (A) Dependence of the crystal 
frequency on MT concentration. (B) Typical QCM signals of frequency change after 
application of 0, 0.5, 5, 20 and 50 µg/mL MT. In inset: Photograph of experimental 
arrangement of QCM. Supporting electrolyte: 0.2 M phosphate buffer (pH 7.0), flow rate 1 
mL min-1 for rinsing the crystal, n = 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moreover the influence of cisplatin concentration on the frequency of the gold electrode modified 
by MT (10 µg mL-1) was studied. This dependence is shown in Figure 7. The blue columns represent 
amounts of the added cisplatin; the red columns show the changes in the frequency after cisplatin 
interaction. It follows from the results obtained that increasing cisplatin concentration resulted in the 
decrease in the frequency. Already after addition of 2.5 µg mL-1 cisplatin, the MT signal was reduced 
by more than 90 %. A concentration 10 µg mL-1 of cisplatin led to a 150% reduction of the signal. 
Based on these results we attempted to calculate amount of cisplatin bonded to the MT-modified 
QCM. In the previous paragraph we noted that one ng of MT caused approx. a 3 Hz decrease in the 
frequency. The highest cisplatin concentration (50 ng) resulted in the frequency change of 54.65 Hz. 
This change shows that 18.33 ng of cisplatin is bonded to the MT-modified QCM. One molecule of 
MT is able to bind up to seven molecules of divalent heavy metal ion  [60,61]. Platinum in cisplatin is 
divalent, so it may be suggested that MT should be able to bind seven molecules of cisplatin. It has 
been reported that cisplatin administration to rabbits yielded the species Pt2Zn5MT [62]. Nevertheless 
in vitro experiments showed that cisplatin has much more higher affinity to MT compared with 
cadmium(II) and zinc(II) ions [4,35]. Therefore we expected that cisplatin can saturate all binding sites 
of a MT standard containing cadmium(II) and zinc(II) only. The gold electrode was modified by 50 ng 
of MT with a theoretical capacity to bind with 17.5 ng of cisplatin. The difference between the 
experimentally estimated value and theoretical value can be related to unspecific interactions between 
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the cysteine moieties of MT and cisplatin. Moreover we can conclude that cisplatin binds to the MT 
structure rapidly and tightly, because the signal corresponding to MT decreased even after interaction 
of a five times lower concentration of cisplatin, compared to that of MT. The association constant of 
platinum to MT KPt-MT = 2.3 × 10-23 was obtained, which is in very good agreement with the result 
derived from the hydrogen-platinum competition [4]. 
 
Figure 6. QCM analysis of MT-cisplatin interactions (various times of interaction (MT: 10 
µg mL-1, cisplatin: 100 µg mL-1), n = 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. QCM analysis of MT-cisplatin interactions, n = 5. 
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3. Materials and Methods 
 
3.1. Chemicals, pH measurements and materials 
 
Rabbit liver MT (MW 7143 g mol-1), containing 5.9 % Cd and 0.5 % Zn, was purchased from 
Sigma Aldrich (St. Louis, USA). The stock standard solutions of metallothionein (MT) was prepared 
with ACS water (Sigma-Aldrich, USA) and stored in the dark at –20 °C. Working standard solutions 
were prepared daily by dilution of the stock solutions with ACS water. The chemotherapeutic drug of 
cisplatin was synthesized and provided by Pliva-Lachema (Brno, Czech Republic). Stock standard 
solutions of cisplatin (500 μg mL-1) were prepared with sodium chloride solution (0.75 M, pH 5.0) and 
stored in the dark at -20 °C. The pH value was measured using WTW inoLab pH meter (Weilheim, 
Germany). Deionised water underwent demineralization by reverse osmosis using the instruments 
Aqua Osmotic 02 (Aqua Osmotic, Tisnov, Czech Republic) and then it was subsequently purified 
using Millipore RG (Millipore Corp., USA, 18 MΏ) – MiliQ water. 
 
3.2. Preparation of biological samples for metallothionein determination 
 
Blood samples were prepared by heat treatment. Briefly, the sample was kept at 99 °C in a 
thermomixer (Eppendorf 5430, USA) for 15 min. with occasional stirring, and then cooled to 4 °C. 
The denatured homogenates were centrifuged at 4 °C, 15,000g for 30 min. (Eppendorf 5402, USA). 
Heat treatment effectively denatures and removes high molecular weight proteins from samples [49]. 
 
3.3. Rats 
 
Male Wistar rats (Faculty of Medicine, Masaryk University, Brno, Czech Republic), 8 weeks old 
(270-280 g), were used in our experiments. Six specimens were exposed to one dose of 1.05 mg of 
cisplatin per kg. Cisplatin was administered intraperitoneally. 
 
3.4. Electrochemical measurements – Brdicka´s reaction 
 
Electrochemical measurements were performed with an AUTOLAB Analyzer (EcoChemie, 
Netherlands) connected to a VA-Stand 663 (Metrohm, Switzerland), by using a standard cell with 
three electrodes. A hanging mercury drop electrode (HMDE) with a drop area of 0.4 mm2 was 
employed as the working electrode. The Ag/AgCl/3M KCl electrode was serving as the reference 
electrode. The glassy carbon electrode was used as the auxiliary electrode. The software GPES 4.9 
supplied by EcoChemie was employed for the smoothing and baseline correction. The principle of the 
adsorptive transfer stripping technique (AdTS) is based on the strong adsorbing of the target molecule 
on the electrode surface at an open electrode circuit. The electrode is washed in the rinsing buffer. The 
electrode is further transferred to the supporting electrolyte and measured. The Brdicka supporting 
electrolyte containing 1 mM Co(NH3)6Cl3 and 1 M ammonia buffer (NH3(aq) + NH4Cl, pH = 9.6) was 
used and changed after five measurements; surface-active agent was not added. The samples of the MT 
were reduced before each measurement by 1 mM tris(2-carboxyethyl)phosphine addition according to 
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[63]. AdTS DPV Brdicka´s reaction parameters were as follows: the initial potential of –0.35 V,  the 
final potential –1.8 V, the modulation time 0.057 s, the time interval 0.2 s, the step potential of 1.05 
mV, the modulation amplitude of 250 mV, Eads = 0 V. All experiments were carried out at 4 °C (Julabo 
F12, Germany). 
 
3.5. Quartz crystal microbalance 
 
QCM measurements were performed by using 8-MHz ATcuts with gold electrodes on both sides 
(diameter 5 mm) supplied by CH Instruments (Austin, TX, USA). The output tube from the cell was 
connected to a peristaltic pump (Pump P-1, Biosciences, Amershan, UK). The measurement 
arrangement consisted of the QCM sensor fixed inside the flow-through cell and only one side was 
exposed to the flowing solutions. Connections were realized by using of the PVC tubing (internal 
diameter 0.15 mm). The crystals settled in the flow-through cell were connected to an oscillator circuit 
(International Manufacturing, Oklahoma City, USA) and the output frequency was determined using a 
universal counter (UZ 2400; UTES/ Grundig, Brno, Czech Republic). Data were displayed and 
recorded by using of the CHI software (CHI, version 7.12, Austin, TX, USA). 
 
3.6 Descriptive statistics 
 
Data were processed by using the MICROSOFT EXCEL® (USA). Results are expressed as mean ± 
the standard deviation (S.D.) unless stated otherwise. 
 
4. Conclusions 
 
We have demonstrated that Brdicka´s reaction can be considered as a suitable tool for the study of 
the interactions of platinum-based therapeutics with metallothionein. The concentration of MT and 
cisplatin used in this study was similar to those found in the body, where the concentrations of these 
compounds ranges from sub-units to units µM [11,21,64,65]. Concerning our findings, we have 
discovered that a new signal appeared after MT-cisplatin interaction, which correlated well both with 
time of interaction and concentration of the drug. The formation of a MT-cisplatin complex was also 
confirmed in the experiments performed in vivo on the male rats which were treated with cisplatin. 
Interaction of MT with cisplatin was also investigated by QCM. It follows that MT-cisplatin 
interaction is relatively rapid and surely plays an important role in the therapy of malignant diseases. 
These results can contribute to simulation of the processes proceeding in vivo and may help during the 
proposal of therapy. 
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